Perspective Therapeutics doses first patients in two Phase 1/2a studies

Perspective Therapeutics (CATX) announced that the first patients were dosed with (212Pb)VMT-alpha-NET and (212Pb)PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tumors, respectively. The first patient was treated with (212Pb)VMT-alpha-NET in a fourth cohort of the company’s ongoing Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors, or NETs. The design of this dosing regimen will help determine whether front-loading could change response kinetics and further improve response rate and tolerability at the same cumulative administered dose. Additionally, the first patient was treated with (212Pb)PSV359 in a third cohort of the company’s Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical (212Pb)PSV359 in patients with solid tumors that express fibroblast activation protein alpha. The company is conducting a multi-center, open-label, dose-escalation, dose-expansion study of (212Pb)VMT-alpha-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies.